Fudan Zhangjiang Third Quarter Report 2024
Announcement of Fudan Zhangjiang on holding the results briefing for the third quarter of 2024
Fudan Zhangjiang: Fudan Zhangjiang H share announcement
Fudan Zhangjiang: Fudan Zhangjiang H share announcement
Fudan Zhangjiang H-share announcement
Fudan Zhangjiang H-share announcement
Fudan Zhangjiang: Fudan Zhangjiang H share announcement
Fudan Zhangjiang H-share announcement
Fudan and Zhangjiang voluntarily disclosed an announcement on the completion of the US Phase II clinical trial of injectable hempofen to treat erythematous moles
Fudan Zhangjiang Announcement on Participating in the 2024 Semi-Annual Pharmaceutical and Biological Products Special Group Performance Briefing
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. voluntarily discloses the announcement of the completion of the first subject enrollment in the phase III clinical trial of injection FDA018 antibody conjugate for the treatment of triple-negative breast cancer.
Announcement from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. regarding the resignation of core technical personnel.
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. 2024 semi-annual equity distribution implementation announcement
Announcement of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.'s special report on the use and placement of fundraising during the first half of 2024.
Announcement of the Resolution of the Sixth Meeting of the Eighth Supervisory Committee of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
Mid-year evaluation report of the 'Improving Efficiency and Returning More' action plan for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. in 2024.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Half-Year Report for 2024.
Announcement from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. regarding the profit distribution plan for the mid-term of 2024.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Half-Yearly Report Summary 2024
Announcement from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. regarding the 2024 interim performance presentation.
No Data
No Data